- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Sun Shield: Protecting Beyond Ultraviolet Light : Episode 1
Opinion
Video
The Solar Spectrum and Impact on Skin Health
Author(s):
An expert discusses how UV radiation makes up about 7% of the sun’s energy and penetrates the skin, causing aging, hyperpigmentation, and inflammation. Visible light and infrared radiation contribute to skin damage, with blue light being more harmful than red light due to its deeper penetration.
Video Player is loading.
Video content above is prompted by the following:
- How do visible light, infrared radiation, and UV radiation differ in terms of wavelength and skin penetration? (NOAA ClimateBits)
- UV radiation—100-400nm; about 7% of sun’s energy
- Visible light—400-700nm; about 43% of sun’s energy
- Infrared radiation—700nm-1mm; about 49% of sun’s energy
- How do visible light and infrared radiation contribute to skin aging, hyperpigmentation, and inflammation?
- Within the visible light spectrum, what types of light are the most detrimental to skin health (ie, blue light vs red light)?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
Key Takeaways on GEP Testing in Melanoma and SCC
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation
Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies
Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children
Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects
Overcoming Therapeutic Inertia in a 25-Year-Old Man with Moderate to Severe Atopic Dermatitis
Safety Considerations in Pediatric Atopic Dermatitis Treatments
Related Content
